Compare JKS & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JKS | WGS |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | China | United States |
| Employees | N/A | 1300 |
| Industry | Semiconductors | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2010 | N/A |
| Metric | JKS | WGS |
|---|---|---|
| Price | $19.19 | $56.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $24.80 | ★ $120.71 |
| AVG Volume (30 Days) | 791.5K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 6.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.98 |
| Revenue Next Year | $14.60 | $25.92 |
| P/E Ratio | ★ N/A | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.37 | $32.21 |
| 52 Week High | $31.88 | $170.87 |
| Indicator | JKS | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 51.16 |
| Support Level | $17.37 | $32.21 |
| Resistance Level | $26.68 | $73.46 |
| Average True Range (ATR) | 1.24 | 4.21 |
| MACD | -0.11 | 1.05 |
| Stochastic Oscillator | 32.74 | 42.45 |
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), the Americas, Europe, Asia Pacific, and the Rest of the world.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.